{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T02:45:03Z","timestamp":1778813103642,"version":"3.51.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Lung neuroendocrine neoplasms (NENs) represent about 20% of all lung cancers. Few therapeutic options are available for atypical carcinoids (ACs). Single-agent temozolomide (TEM) is active in lung NENs, but whether the addition of capecitabine (CAPTEM) is associated with improved outcomes, is unknown. We sought to investigate the TEM-based therapies (TEM or CAPTEM) in patients with advanced AC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Material and methods<\/jats:title>\n            <jats:p>This was a retrospective analysis of prospectively collected data from patients with AC of the lung referred to our institution from January 2003 to January 2023 who have received chemotherapy with either TEM or CAPTEM as any line treatment. Primary endpoint was progression free survival (PFS), secondary endpoints included overall response rate (ORR) and overall survival (OS).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In this study we included 31 patients with advanced AC. Median Ki-67 was 14.4% (3\u201330). CAPTEM in 17 patients (54.8%), while TEM was administered in 14 patients (45.2%). Overall, ORR was 39% (<jats:italic>N<\/jats:italic>\u2009=\u200912\/31, all partial responses), while median PFS and OS were 57.4 months (95%CI: 43.2\u201371.7) and 24.4 months (95% confidence interval [95%CI]: 14.7\u201334.1). Median PFS was 33.9 months (15.6\u201352.1) in the CAPTEM group, while it was 15.5 (7.3\u201323.8) in the TEM group (<jats:italic>p<\/jats:italic>\u2009=\u20090.047). When adjusting for potential confounding factors, treatment with TEM vs CAPTEM retained its independent association with an increased risk of progression (HR: 4.01 [95%CI: 1.18\u201313.68]; <jats:italic>p<\/jats:italic>\u2009=\u20090.027).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Treatment with CAPTEM is associated with longer PFS than TEM alone in patients with AC. Prospective studies with larger sample size are needed to validate this finding.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s12020-025-04171-5","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T13:47:08Z","timestamp":1737726428000},"page":"660-667","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Capecitabine and temozolomide or temozolomide alone in patients with atypical carcinoids"],"prefix":"10.1007","volume":"88","author":[{"given":"Linda","family":"Galvani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arianna","family":"Zappi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Pusceddu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Gelsomino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"La Salvia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Oldani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2789-4289","authenticated-orcid":false,"given":"Francesco","family":"Panzuto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Andrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3069-7630","authenticated-orcid":false,"given":"Giuseppe","family":"Lamberti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Campana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"issue":"aprile 4","key":"4171_CR1","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.annonc.2021.01.003","volume":"32","author":"E Baudin","year":"2021","unstructured":"E. Baudin, M. Caplin, R. Garcia-Carbonero, N. Fazio, P. Ferolla, P.L. Filosso et al. Lung and thymic carcinoids: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2606. Ann. Oncol. 32(aprile 4), 439\u2013451 (2021)","journal-title":"Ann. Oncol."},{"issue":"luglio 7","key":"4171_CR2","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","volume":"32","author":"AMC Dingemans","year":"2021","unstructured":"A.M.C. Dingemans, M. Fr\u00fch, A. Ardizzoni, B. Besse, C. Faivre-Finn, L.E. Hendriks et al. Small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2606. Ann. Oncol. 32(luglio 7), 839\u2013853 (2021)","journal-title":"Ann. Oncol."},{"issue":"luglio 1","key":"4171_CR3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/ejcts\/ezu404","volume":"48","author":"PL Filosso","year":"2015","unstructured":"P.L. Filosso, O. Rena, F. Guerrera, P. Moreno Casado, D. Sagan, F. Raveglia et al. Clinical management of atypical carcinoid and large-cell neuroendocrine carcinoma: a multicentre study on behalf of the European association of thoracic surgeons (ESTS) neuroendocrine tumours of the lung working group. Eur. J. Cardiothorac. Surg. 48(luglio 1), 55\u201364 (2015)","journal-title":"Eur. J. Cardiothorac. Surg."},{"issue":"marzo 3","key":"4171_CR4","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1097\/JTO.0000000000000419","volume":"10","author":"CE Steuer","year":"2015","unstructured":"C.E. Steuer, M. Behera, S. Kim, Z. Chen, N.F. Saba, R.N. Pillai et al. Atypical carcinoid tumor of the lung: a surveillance, epidemiology, and end results database analysis. J. Thorac. Oncol. 10(marzo 3), 479\u2013485 (2015)","journal-title":"J. Thorac. Oncol."},{"issue":"agosto 8","key":"4171_CR5","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1093\/annonc\/mdv041","volume":"26","author":"ME Caplin","year":"2015","unstructured":"M.E. Caplin, E. Baudin, P. Ferolla, P. Filosso, M. Garcia-Yuste, E. Lim et al. Pulmonary neuroendocrine (carcinoid) tumors: European neuroendocrine tumor society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann. Oncol. 26(agosto 8), 1604\u20131620 (2015)","journal-title":"Ann. Oncol."},{"issue":"giugno 11","key":"4171_CR6","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3747\/co.25.3808","volume":"25","author":"B Melosky","year":"2018","unstructured":"B. Melosky, Advanced typical and atypical carcinoid tumours of the lung: management recommendations. Curr. Oncol. 25(giugno 11), 86\u201393 (2018)","journal-title":"Curr. Oncol."},{"issue":"dicembre 1","key":"4171_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s40169-019-0238-5","volume":"8","author":"M Torniai","year":"2019","unstructured":"M. Torniai, L. Scortichini, F. Tronconi, C. Rubini, F. Morgese, S. Rinaldi et al. Systemic treatment for lung carcinoids: from bench to bedside. Clin. Transl. Med. 8(dicembre 1), e22 (2019)","journal-title":"Clin. Transl. Med."},{"issue":"dicembre 9808","key":"4171_CR8","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","volume":"378","author":"ME Pavel","year":"2011","unstructured":"M.E. Pavel, J.D. Hainsworth, E. Baudin, M. Peeters, D. H\u00f6rsch, R.E. Winkler et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378(dicembre 9808), 2005\u20132012 (2011)","journal-title":"Lancet"},{"issue":"marzo 10022","key":"4171_CR9","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","volume":"387","author":"JC Yao","year":"2016","unstructured":"J.C. Yao, N. Fazio, S. Singh, R. Buzzoni, C. Carnaghi, E. Wolin et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 387(marzo 10022), 968\u2013977 (2016)","journal-title":"Lancet"},{"issue":"settembre","key":"4171_CR10","doi-asserted-by":"publisher","first-page":"ix377","DOI":"10.1016\/S0923-7534(20)33726-1","volume":"23","author":"M Pavel","year":"2012","unstructured":"M. Pavel, B. Wiedenmann, J. Capdevila, J.W. Valle, W.W. De Herder, C. Metzer et al. Ramsete: a single-arm, multicenter, single-stage phase II Trial of Rad001 (EVEROLIMUS) in Advanced and metastatic silent neuro-endocrine tumours in Europe: analysis by tumor origin. Ann. Oncol. 23(settembre), ix377 (2012)","journal-title":"Ann. Oncol."},{"issue":"aprile","key":"4171_CR11","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1159\/000402752","volume":"44","author":"P Ferolla","year":"2015","unstructured":"P. Ferolla, Medical therapy of pulmonary neuroendocrine neoplasms: targeted, symptomatic and chemotherapy. Front. Horm. Res. 44(aprile), 193\u2013197 (2015)","journal-title":"Front. Horm. Res."},{"issue":"giugno 3","key":"4171_CR12","doi-asserted-by":"publisher","first-page":"100478","DOI":"10.1016\/j.esmoop.2022.100478","volume":"7","author":"B Kiesewetter","year":"2022","unstructured":"B. Kiesewetter, P. Mazal, E. Kretschmer-Chott, M.E. Mayerhoefer, M. Raderer, Pulmonary neuroendocrine tumours and somatostatin receptor status: an assessment of unlicensed use of somatostatin analogues in the clinical practice. ESMO Open. 7(giugno 3), 100478 (2022)","journal-title":"ESMO Open."},{"issue":"gennaio 2","key":"4171_CR13","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/cncr.25425","volume":"117","author":"JR Strosberg","year":"2011","unstructured":"J.R. Strosberg, R.L. Fine, J. Choi, A. Nasir, D. Coppola, D.T. Chen et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 117(gennaio 2), 268\u2013275 (2011)","journal-title":"Cancer"},{"issue":"16_suppl","key":"4171_CR14","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1200\/JCO.2022.40.16_suppl.4004","volume":"40","author":"PL Kunz","year":"2022","unstructured":"P.L. Kunz, N. Graham, P.J. Catalano, H. Nimeiri, G.A. Fisher, T.A. Longacre et al. A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: final analysis of efficacy and evaluation of MGMT (ECOG-ACRIN E2211). JCO 40(16_suppl), 4004 (2022)","journal-title":"JCO"},{"issue":"settembre 9","key":"4171_CR15","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1530\/ERC-16-0147","volume":"23","author":"M Cives","year":"2016","unstructured":"M. Cives, M. Ghayouri, B. Morse, M. Brelsford, M. Black, A. Rizzo et al. Analysis of potential response predictors to capecitabine\/temozolomide in metastatic pancreatic neuroendocrine tumors. Endocr. Relat. Cancer 23(settembre 9), 759\u2013767 (2016)","journal-title":"Endocr. Relat. Cancer"},{"issue":"9","key":"4171_CR16","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1159\/000513218","volume":"111","author":"A Bongiovanni","year":"2021","unstructured":"A. Bongiovanni, C. Liverani, F. Foca, V. Fausti, G. Di Menna, L. Mercatali et al. Temozolomide alone or combined with capecitabine for the treatment of metastatic neuroendocrine neoplasia: a \u00abReal-World\u00bb data analysis. Neuroendocrinology 111(9), 895\u2013906 (2021)","journal-title":"Neuroendocrinology"},{"issue":"luglio","key":"4171_CR17","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ejca.2016.03.082","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"L.H. Schwartz, L. Seymour, S. Liti\u00e8re, R. Ford, S. Gwyther, S. Mandrekar et al. RECIST 1.1 - Standardisation and disease-specific adaptations: perspectives from the RECIST working group. Eur. J. Cancer 62(luglio), 138\u2013145 (2016)","journal-title":"Eur. J. Cancer"},{"issue":"aprile","key":"4171_CR18","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ejca.2016.11.034","volume":"75","author":"I Sullivan","year":"2017","unstructured":"I. Sullivan, G. Le Teuff, J. Guigay, C. Caramella, A. Berdelou, S. Leboulleux et al. Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids. Eur. J. Cancer 75(aprile), 259\u2013267 (2017)","journal-title":"Eur. J. Cancer"},{"key":"4171_CR19","unstructured":"NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae), neuroendocrine and adrenal tumors, version 1.2023 \u2014 (august 2), (2023) https:\/\/arupconsult.com\/reference\/nccn-neuroendocrine-and-adrenal-tumors-version-12023"},{"issue":"2","key":"4171_CR20","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1159\/000354760","volume":"98","author":"J Crona","year":"2013","unstructured":"J. Crona, I. Fanola, D.P. Lindholm, P. Antonodimitrakis, K. \u00d6berg, B. Eriksson et al. Effect of temozolomide in patients with metastatic bronchial carcinoids. Neuroendocrinology 98(2), 151\u2013155 (2013)","journal-title":"Neuroendocrinology"},{"key":"4171_CR21","doi-asserted-by":"crossref","unstructured":"P. Ferolla, A. Berruti, F. Spada, M.P. Brizzi, T. Ibrahim, R. Marconcini et al. Efficacy and safety of lanreotide autogel and temozolomide combination therapy in progressive thoracic neuroendocrine tumors (carcinoid): results from the phase 2 ATLANT study. Neuroendocrinology. 113, 332\u2013342 (2022)","DOI":"10.1159\/000526811"},{"issue":"agosto 1","key":"4171_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11276-9","volume":"10","author":"N Alcala","year":"2019","unstructured":"N. Alcala, N. Leblay, A.A.G. Gabriel, L. Mangiante, D. Hervas, T. Giffon et al. Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids. Nat. Commun. 10(agosto 1), 3407 (2019)","journal-title":"Nat. Commun."},{"issue":"novembre 2","key":"4171_CR23","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.lungcan.2014.08.012","volume":"86","author":"CR Chong","year":"2014","unstructured":"C.R. Chong, L.J. Wirth, M. Nishino, A.B. Chen, L.M. Sholl, M.H. Kulke et al. Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors. Lung Cancer 86(novembre 2), 241\u2013246 (2014)","journal-title":"Lung Cancer"},{"issue":"marzo 7","key":"4171_CR24","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1038\/sj.bjc.6605618","volume":"102","author":"NC Turner","year":"2010","unstructured":"N.C. Turner, S.J. Strauss, D. Sarker, R. Gillmore, A. Kirkwood, A. Hackshaw et al. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br. J. Cancer 102(marzo 7), 1106\u20131112 (2010)","journal-title":"Br. J. Cancer"},{"issue":"aprile 5","key":"4171_CR25","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s00280-006-0306-6","volume":"59","author":"E Bajetta","year":"2007","unstructured":"E. Bajetta, L. Catena, G. Procopio, S. De Dosso, E. Bichisao, L. Ferrari et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother. Pharmacol. 59(aprile 5), 637\u2013642 (2007)","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"agosto 15","key":"4171_CR26","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1002\/cncr.24384","volume":"115","author":"PA Cassier","year":"2009","unstructured":"P.A. Cassier, T. Walter, B. Eymard, P. Ardisson, M. Perol, C. Paillet et al. Gemcitabine and oxaliplatin combination chemotherapy for metastatic well\u2010differentiated neuroendocrine carcinomas: a single\u2010center experience. Cancer 115(agosto 15), 3392\u20133399 (2009)","journal-title":"Cancer"},{"issue":"ottobre 41","key":"4171_CR27","doi-asserted-by":"publisher","first-page":"e12784","DOI":"10.1097\/MD.0000000000012784","volume":"97","author":"Y Lu","year":"2018","unstructured":"Y. Lu, Z. Zhao, J. Wang, W. Lv, L. Lu, W. Fu et al. Safety and efficacy of combining capecitabine and temozolomide (CAPTEM) to treat advanced neuroendocrine neoplasms: a meta-analysis. Medicine 97(ottobre 41), e12784 (2018)","journal-title":"Medicine"},{"issue":"4","key":"4171_CR28","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1159\/000500135","volume":"109","author":"E Chatzellis","year":"2019","unstructured":"E. Chatzellis, A. Angelousi, K. Daskalakis, M. Tsoli, K.I. Alexandraki, E. Wachu\u0142a et al. Activity and safety of standard and prolonged capecitabine\/temozolomide administration in patients with advanced neuroendocrine neoplasms. Neuroendocrinology 109(4), 333\u2013345 (2019)","journal-title":"Neuroendocrinology"},{"issue":"giugno 3","key":"4171_CR29","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1007\/s12020-017-1474-3","volume":"60","author":"D Campana","year":"2018","unstructured":"D. Campana, T. Walter, S. Pusceddu, F. Gelsomino, E. Graillot, N. Prinzi et al. Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study. Endocrine 60(giugno 3), 490\u2013498 (2018)","journal-title":"Endocrine"},{"issue":"agosto 8","key":"4171_CR30","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1530\/ERC-16-0117","volume":"23","author":"J Cros","year":"2016","unstructured":"J. Cros, O. Hentic, V. Rebours, M. Zappa, N. Gille, N. Theou-Anton et al. MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors. Endocr. Relat. Cancer 23(agosto 8), 625\u2013633 (2016)","journal-title":"Endocr. Relat. Cancer"},{"issue":"aprile 4","key":"4171_CR31","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.dld.2019.02.001","volume":"51","author":"A Lemelin","year":"2019","unstructured":"A. Lemelin, M. Barritault, V. Hervieu, L. Payen, J. P\u00e9ron, A. Couvelard et al. O6-methylguanine-DNA methyltransferase (MGMT) status in neuroendocrine tumors: a randomized phase II study (MGMT-NET). Dig. Liver Dis. 51(aprile 4), 595\u2013599 (2019)","journal-title":"Dig. Liver Dis."},{"key":"4171_CR32","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.2147\/CMAR.S372776","volume":"14","author":"G Arrivi","year":"2022","unstructured":"G. Arrivi, M. Verrico, M. Roberto, G. Barchiesi, A. Faggiano, P. Marchetti et al. Capecitabine and temozolomide (CAPTEM) in advanced neuroendocrine neoplasms (NENs): a systematic review and pooled analysis. Cancer Manag. Res. 14, 3507\u20133523 (2022)","journal-title":"Cancer Manag. Res."},{"issue":"gennaio 1","key":"4171_CR33","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1634\/theoncologist.2019-0361","volume":"25","author":"T Al-Toubah","year":"2020","unstructured":"T. Al-Toubah, B. Morse, J. Strosberg, Capecitabine and temozolomide in advanced lung neuroendocrine neoplasms. Oncologist 25(gennaio 1), e48\u2013e52 (2020)","journal-title":"Oncologist"},{"issue":"5","key":"4171_CR34","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1159\/000502864","volume":"110","author":"G Papaxoinis","year":"2020","unstructured":"G. Papaxoinis, Z. Kordatou, L. McCallum, M. Nasralla, A. Lamarca, A. Backen et al. Capecitabine and temozolomide in patients with advanced pulmonary carcinoid tumours. Neuroendocrinology 110(5), 413\u2013421 (2020)","journal-title":"Neuroendocrinology"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04171-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-025-04171-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04171-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T07:47:34Z","timestamp":1747036054000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-025-04171-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["4171"],"URL":"https:\/\/doi.org\/10.1007\/s12020-025-04171-5","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]},"assertion":[{"value":"28 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"F.G. received honoraria for speaker\/advisory roles from Servier, Eli Lilly, Iqvia, Merck Serono, Amgen, and Bristol-Myers Squibb outside the present work. D.C. received honoraria for speaker\/advisory roles from Ipsen, Novartis and Esteve outside the present work. F.P., A.L.S., G.L., L.G., A.Z., S.P., and S.O.: no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by local IRB (Comitato Etico indipendente, IRCCS Policlinico Sant\u2019Orsola-Malpighi of Bologna, protocol code: SOCRATE, 787\/2019\/Oss\/AOUBo) and was conducted in accordance with the principles of the Declaration of Helsinki (revision of Edinburgh, 2000).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}